Prevalence of Major Depressive Disorder in Patients Diagnosed with Breast Cancer in Southwest Nigeria
Published: 2022-11-11
Page: 131-138
Issue: 2022 - Volume 5 [Issue 2]
Oluwafunbi Opadola *
Department of Psychiatry, LAUTECH Teaching Hospital Ogbomoso, Oyo State, Nigeria.
Taiwo Alatishe
Department of Psychiatry, LAUTECH Teaching Hospital Ogbomoso, Oyo State, Nigeria.
Babatunde Suleiman
Department of Psychiatry, LAUTECH Teaching Hospital Ogbomoso, Oyo State, Nigeria.
Omodele Opadola
Department of Anesthesia, Obafemi Awolowo University Teaching Hospital Complex, Ile-Ife, Osun State, Nigeria.
Samson Ojedokun
Department of Chemical Pathology, LAUTECH Teaching Hospital Ogbomoso, Oyo State, Nigeria.
Olaitan Oladele
Department of Psychiatry, LAUTECH Teaching Hospital Ogbomoso, Oyo State, Nigeria.
*Author to whom correspondence should be addressed.
Abstract
Background: Globally, breast cancer remains the commonest cancer diagnosis among women which is usually accompanied by an array of psychological distress including depression. This study aimed to determine the prevalence of major depression among people living with breast cancer in Ogbomoso, Oyo State Nigeria.
Methods: The study was a comparative cross-sectional design conducted among 222 women with breast cancer attending the General Surgery Outpatient clinic and a comparison control group of age-matched women without a history of breast cancer. Data were obtained using a self-administered questionnaire while other clinical details were extracted from their hospital records following informed consent. The PHQ-9 and MINI were instruments used in the diagnosis of depression and Major depressive disorder respectively. Data obtained were analyzed using SPSS version 21.
Results: Of the 222 respondents, 70 have been diagnosed with breast cancer with a mean age of 35.2 ± 8.6. It was observed that 34.3% had major depression while 38.6% had minor depression and 27.1% were not depressed using PHQ-9. Of the respondents positive for the PHQ screening, 8 fulfilled the criteria for major depression after screening with MINI.
Conclusion: The prevalence of major depressive disorder was higher among women with breast cancer (11.42%) compared to age-matched control without breast cancer (1.97%).
Keywords: Depression, major depressive disorder, breast cancer, Ogbomoso, Nigeria
How to Cite
Downloads
References
Yahoo. COVID-19 pandemic. Yahoo Search; 2022.
Wynn TA. Cellular and molecular mechanism of fibrosis. J Pathol. 2008;214 (2):199-210.
Rybinski B, Cukieman E. The wound healing, chronic fibrosis and cancer progressing triad. Physiol Genomics. 2014; 46(7):223-244.
Liau MC, Baker LL. Wound healing, evolution of cancer and war on cancer. Intl Res J Oncol. 2021;4(3):13-20.
Liau MC, Baker LL. Cancer arises as a consequence of wound not healing properly. Thus, perfection of wound healing must be the most appropriate strategy to win the war on cancer. Adv Complement Alt Med. 2021;6(3):584-586.
Liau MC, Szopa M, Burzynski B, Burzynski SR. Chemo-surveillance: A novel concept of the natural defense mechanism against cancer. Drug Exptl Clin Res. 1989;13 (5):72-82.
Liau MC, Craig CL. Chemo-surveillance as a natural mechanism to ensure perfection of wound healing to avoid cancer evolution and to cure cancer. In: New Horizons in Medicine and Medical Research. 2022;6(3).
Print ISBN: 978-93-5547-607-4
Liau MC, Baker LL. Destruction promotes the proliferation of progenitor stem cells and cancer stem cells. Therefore, non-destruction strategy is a better choice for cancer therapy. J Pharmacol Pharmaceu Pharmacovigi. 2020;4:029.
DOI:10.24966/PPP-5649/100029
Liau MC, Baker LL. The functionality of chemo-surveillance dictates the success of wound healing as well as cancer therapy. Nov Res Sci. 2021;7(2):1-3.
Liau MC, Craig CL. Wound healing metabolites to heal cancer and unhealed wounds. Intl Res J Oncol. 2022;6(3):8-20.
Liau MC, Chang CF, Saunder GF, Tsai YH. S-Adenosylhomocysteine hydrolases as the primary target enzymes in androgen regulation of methylation complexes. Arch Biochem Biophys. 1981;208(1):261-272.
Liau MC, Zhuang P, Chiou GCY. Identification of the tumor factor of abnormal methylation enzymes as the catalytic subunit of telomerase. Chin Oncol Cancer Res. 2010;7(2):86-96.
Liau MC, Lee SS, Burzynski SR. Hypomethylation of nucleic acids: A key to the induction of terminal differentiation. Intl J Exptl Clin Chemotherapy. 1989;2(2): 187-199.
Liau MC, Kim JH, Fruehauf JP. In pursuance of differentiation inducers for the differentiation therapy of cancer. J Cancer Tumor Intl. 2020;10(2):29-47.
Liau MC, Kim JH, Fruehauf JP. Arachidonic acid and its metabolites as the surveillance differentiation inducers to protect healthy people from becoming cancer patients. Clin Pharmacol Toxicol Res. 2021;4(1):7-10.
Liau MC, Liau CP. Methyltransferase inhibitors as excellent differentiation helper inducers for differentiation therapy of cancer. Bull Chin Cancer. 2002;11(3): 166-168.
Liau MC, Fruehauf PA, Zheng ZH, Fruehauf JP. Development of synthetic differentiation agent formulations for the prevention and therapy of cancer via targeting of cancer stem cells. Cancer Stud Ther J. 2019;4(1):1-15.
Liau MC, Kim JH, Fruehauf JP. Potentiation of ATRA activity in HL-60 cells by targeting of methylation enzymes. J Pharmacol Pharmaceu Pharmacovigi. 2019;3(1):009.
DOI:10.24966/PPP-5649/100009
Liau MC, Craig CL. On the mechanism of wound healing, and the impact of wound on cancer evolution and cancer therapy. Intl Res J Oncol. 2021;5(3):25-31.
Itkin T, Rafii S. Leukemia cells “gas up” leaky bone marrow blood vessels. Cancer Cell. 2017;32(3):276-278.
Passaro D, Di Trullo A, Abarrategi A, Rouault-Pierre K, Foster K, et al. Increased vascular permeability in the bone marrow microenvironment contributes to disease progression and drug response in acute myeloid leukemia. Cancer Cell. 2017;32 (3):324-341.
Virchow R. Die cellular pathilogie in ihrer begrundung auf physiologische und pathologische gewebelehve. Hirschwald. 1858;16:440.
Dvorak HF. Tumors: Wound that do not heal. N Engl J Med. 1986;315(26): 1650-1659.
MacCarthy-Morrough L, Martin P. The hallmarks of cancer are also the hallmarks of wound healing. Science Signaling. 2020;13:648.
Liau MC, Kim JH, Fruehauf JP. Destabilizaion of abnormal methylation enzymes: Nature’s way to eradicate cancer stem cells. Online J Complement Alt Med. 2019;2(5): OJCAM.MS.ID.000546.
DOI:10.33542/OJCAM.2019.02.000546
Liau MC. Pharmaceutical composition inducing cancer cell differentiation and the use for treatment and prevention of cancer thereof. US Patent. 2007;7232578:82.
Feng F, Li Q, Ling CQ, Zhang Y Qin F, Wang H, et al. Phase III clinical trials of the cell differentiation agent-2 (CDA-2): Therapeutic efficacy on breast cancer, non-small cell lung cancer and primary hepatoma. Chin J Clin Oncol. 2005;2(4): 706-716.
Liau MC, Kim JH, Fruehauf JP. Destabilization of abnormal methylation enzymes to combat cancer: The nature’s choice to win the war on cancer. Lambert Academic Publishing. 2020;978-620-2-66889-7.
Liau MC, Fruehauf JP. It has been half a century since President declared war on cancer: Destabilization of abnormal methylation enzymes has the blessing of the nature to win the war on cancer. Adv Complement Alt Med. 2020;6(3):538-539.
Liau MC, Baker LL. Eradication of cancer stem cells to win the war on cancer. Nov Res Sci. 2021;6(5):1-3.
Liau MC, Baker LL. Cell differentiation agent formulations to win the war on cancer. Cancer Sci Res. 2022;5(2):1-4.